Lakeshore Financial Planning Inc. Buys New Stake in Pfizer Inc. (NYSE:PFE)

Lakeshore Financial Planning Inc. bought a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,343 shares of the biopharmaceutical company’s stock, valued at approximately $327,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Wayfinding Financial LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $214,000. Goodman Financial Corp lifted its position in Pfizer by 5.5% in the fourth quarter. Goodman Financial Corp now owns 432,271 shares of the biopharmaceutical company’s stock worth $11,468,000 after buying an additional 22,609 shares during the last quarter. DCF Advisers LLC lifted its position in Pfizer by 49.5% in the fourth quarter. DCF Advisers LLC now owns 51,350 shares of the biopharmaceutical company’s stock worth $1,362,000 after buying an additional 17,000 shares during the last quarter. Douglass Winthrop Advisors LLC lifted its position in Pfizer by 78.2% in the fourth quarter. Douglass Winthrop Advisors LLC now owns 85,776 shares of the biopharmaceutical company’s stock worth $2,276,000 after buying an additional 37,653 shares during the last quarter. Finally, Northwest & Ethical Investments L.P. lifted its position in Pfizer by 0.6% in the fourth quarter. Northwest & Ethical Investments L.P. now owns 265,072 shares of the biopharmaceutical company’s stock worth $7,032,000 after buying an additional 1,541 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on PFE shares. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

PFE stock opened at $26.17 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50-day moving average price of $26.18 and a 200 day moving average price of $27.07. The company has a market capitalization of $148.29 billion, a P/E ratio of 18.56, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.